

PROVINCIAL FUNDING SUMMARY

Ribociclib (Kisqali) + Fulvestrant for Advanced or Metastatic Breast Cancer (pCODR 10195)

pERC Recommendation: Reimburse with clinical criteria and/or conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: May 7, 2020

This information is current as of October 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration		
AB	Under provincial consideration		
SK	Funded	Aug 1, 2020	<ul style="list-style-type: none"> •In combination with Fulvestrant for treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (ABC), either as initial therapy, or following disease progression in previously treated patients •Eligible patients include men and women independent of their menopausal status; pre and peri-menopausal women must be rendered postmenopausal, either chemically or surgically, and should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist or bilateral salpingo-oophorectomy •Patients should have good performance status and not have active or uncontrolled metastases to the central nervous system •Treatment may continue until disease progression or unacceptable toxicity
MB	Under provincial consideration		
ON	Under provincial consideration		
NS	Under provincial consideration		

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NB	Funded	Sep 17, 2020	In combination with fulvestrant for the treatment of patients with hormone receptor positive, HER2 negative advanced or metastatic breast cancer who: <ul style="list-style-type: none"> • have not received prior endocrine therapy or have experienced disease progression on endocrine therapy, and • have received up to one prior chemotherapy for advanced or metastatic disease, and • do not have active or uncontrolled metastases to the central nervous system. Renewal criteria: <ul style="list-style-type: none"> • Written confirmation that the patient has responded to treatment and there is no evidence of disease progression. Clinical Notes: <ol style="list-style-type: none"> 1. Pre- and peri-menopausal women must be treated with a luteinizing hormone-releasing hormone agonist. 2. Patients must have a good performance status. 3. Treatment should be discontinued upon disease progression or unacceptable toxicity. Claim Notes: <ul style="list-style-type: none"> • Requests will not be considered for patients who experience disease progression on a CDK4/6 inhibitor, fulvestrant or everolimus. • Initial approval period: 1 year. • Renewal approval period: 1 year.
NL	Under provincial consideration		
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.